INSIGHT-AHP: A Study to Characterize the Prevalence of Acute Hepatic Porphyria (AHP) in Patients With Clinical Presentation and History Consistent With AHP

Acute Hepatic Porphyria Clinical Trial

Official title:
INSIGHT-AHP: A Study to Characterize the Prevalence of Acute Hepatic Porphyria (AHP) in Patients With Clinical Presentation and History Consistent With AHP

Status Terminated

Clinical Trial Summary

This study will use specific diagnostic tests on a group of patients who are experiencing symptoms typical of acute hepatic porphyria (AHP) to determine how many have the condition, and to potentially help improve the diagnostic process for patients in the future.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Acute Hepatic Porphyria
Acute Intermittent Porphyria (AIP)
ALA Dehydratase Deficient Porphyria (ADP)
Hepatic Porphyrias
Hereditary Coproporphyria (HCP)
Porphyria Acute
Porphyria, Acute Intermittent
Porphyria, Erythropoietic
Porphyrias
Variegate Porphyria (VP)

Clinical Trial Details

NCT number	NCT03547297
Study type	Observational
Source	Alnylam Pharmaceuticals
Contact
Status	Terminated
Phase
Start date	May 29, 2018
Completion date	January 15, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03338816` - ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP)	Phase 3
Not yet recruiting	`NCT04923516` - Prevalence of Acute Hepatic Porphyria
Recruiting	`NCT05344599` - Evaluating the Prevalence of Acute Hepatic Porphyria in Postural Tachycardia Syndrome
Completed	`NCT02240784` - EXPLORE: A Natural History Study of Acute Hepatic Porphyria (AHP)
Recruiting	`NCT04883905` - ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)
Approved for marketing	`NCT04056481` - Expanded Access Protocol of Givosiran for Patients With Acute Hepatic Porphyria